<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494466</url>
  </required_header>
  <id_info>
    <org_study_id>GK6</org_study_id>
    <nct_id>NCT02494466</nct_id>
  </id_info>
  <brief_title>Preoperative Use of Montelukast Sodium</brief_title>
  <official_title>The Effects on Airway Reactivity of the Use of Preoperative Montelukast Sodium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umraniye Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umraniye Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supraglottic airway equipment used during anaesthesia application can lead to airway
      reactivity or even larynx spasm in sensitive children.

      Montelukast Sodium, used in asthma treatment, is a cysteinyl leukotriene Type 1 antagonist
      which reduces leukotriene C4, leukotriene D4 and leukotriene E4 synthesis. The use of
      Montelukast Sodium in airway reactivity is known to reduce the need for bronchodilator and
      corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will comprise 30 american society of anesthesiology (ASA) I-III patients, aged 4-8
      years, undergoing inguinal hernia surgery. Patients will exclude if receiving asthma
      treatment, if they had upper respiratory tract infection in the last week and if the
      laryngeal mask airway (LMA) could not be placed at a single attempt.

      Patients will be separated into 3 groups as Group E (n=10) with high immunoglobulin E (IgE),
      Group C (n=10) with normal IgE and Group M (n=10) who were administered with 4mg peroral
      Montelukast Sodium, 10 days before surgery because of high IgE.

      With spontaneous breathing after anaesthesia induction, a classic LMA will be placed.
      Anaesthesia will be maintained with a mixture of 1.3 minimum alveolar concentration (MAC)
      sevoflurane 500%2 - N2O. At 5-minute intervals, oxygen saturation (sPO2), End-Tidal carbon
      dioxide, Heart Rate, tidal volume (VT), respiratory rate (f) and peak airway pressure (PAP)
      will be monitored and coughing, apnea, laryngospasm , bronchospasm, desaturation and need for
      steroids will be noted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with bronchospasm as a Measure of airway reactivity</measure>
    <time_frame>during the operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with laryngospasm as a Measure of airway reactivity</measure>
    <time_frame>during the operation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with apnea</measure>
    <time_frame>during the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>amount of applied steroids</measure>
    <time_frame>during the operation</time_frame>
    <description>steroids can prevent airway reactivity symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak airway pressures as a measurement of airway reactivity</measure>
    <time_frame>during the operation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Airway Reactivity</condition>
  <arm_group>
    <arm_group_label>Group E (n=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with high Ig E levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (n=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with normal Ig E levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M (n=10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.</description>
    <arm_group_label>Group E (n=10)</arm_group_label>
    <arm_group_label>Group C (n=10)</arm_group_label>
    <arm_group_label>Group M (n=10)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing inguinal hernia surgery

        Exclusion Criteria:

          -  If receiving asthma treatment,

          -  If they had URTI in the last week and

          -  If LMA could not be placed at a single attempt.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nurten Bakan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unraniye training and research hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gulsah Karaoren</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Casares-Alonso I, Cano-Garcinuño A, Blanco-Quirós A, Pérez-García I. Anti-asthmatic prescription variability in children according to age. Allergol Immunopathol (Madr). 2015 Jul-Aug;43(4):383-91. doi: 10.1016/j.aller.2014.05.010. Epub 2014 Oct 23.</citation>
    <PMID>25444114</PMID>
  </reference>
  <results_reference>
    <citation>Bush A. Montelukast in paediatric asthma: where we are now and what still needs to be done? Paediatr Respir Rev. 2015 Mar;16(2):97-100. doi: 10.1016/j.prrv.2014.10.007. Epub 2014 Dec 12. Review.</citation>
    <PMID>25499571</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 7, 2015</last_update_submitted>
  <last_update_submitted_qc>July 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umraniye Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Gulsah Karaoren</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Airway Resistance</keyword>
  <keyword>montelukast sodium</keyword>
  <keyword>laryngeal mask airway</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

